IceCure Medical Ltd. Files Prospectus for Rights Offering, Subscription Period Set to Expire on July 28, 2025

Reuters
Jul 24
<a href="https://laohu8.com/S/ICCM">IceCure Medical Ltd.</a> Files Prospectus for Rights Offering, Subscription Period Set to Expire on July 28, 2025

IceCure Medical Ltd., a company specializing in minimally-invasive cryoablation technology for tumor destruction, has filed a prospectus related to its rights offering with the U.S. Securities and Exchange Commission. The offering, which was declared effective on July 9, 2025, allows holders of the company's ordinary shares as of the record date to purchase up to a total of 10,000,000 units. Shareholders were distributed non-transferable subscription rights at no charge. The prospectus provides detailed information about the offering and is available on the SEC's website, while inquiries can be directed to Broadridge Corporate Issuer Solutions, LLC, the appointed Information Agent.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN36962) on July 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10